SAN FRANCISCO, June 1, 2017 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") announced today that it has entered into an agreement with the General Hospital Corporation (Massachusetts General Hospital) for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform, in support of HIV vaccine research. The research led by Daniel Lingwood at the Ragon Institute of MGH, MIT and Harvard, will test methods to transduce antibody responses in universal HIV vaccine design.
"Trianni is delighted to partner with Dr. Lingwood," stated Dr. David Meininger, Trianni's Chief Business Officer. "We are certain that the complete human antibody repertoire found in The Trianni Mouse™, makes it the best platform for use in Dr. Lingwood's HIV vaccine research."
No financial details were disclosed.
About Trianni, Inc.
Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI's lead technology, The Trianni Mouse™, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform. The company is headquartered in San Francisco, CA. Additional information about TRIANNI is available through its corporate website, www.trianni.com.
Contact- Trianni, Inc.
Chief Business Officer
Director of Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trianni-signs-agreement-with-massachusetts-general-hospital-for-use-of-the-trianni-mouse-in-hiv-vaccine-research-300466851.html
SOURCE Trianni, Inc.